Three questions settle it. Do you need an FDA-approved product for a reason printed on its label, is your plan realistically going to pay, and how much live clinician time do you want? Ro is brand only and organized around insurance. Mochi sells a membership with video visits, a dietitian and a flat-priced compounded option.
Start with the reason for treating, not the price
Approved labeling is the part of this decision a reader can verify independently, and it does more work than most comparisons allow. Zepbound carries two indications: long-term weight reduction in adults with obesity or with overweight plus a weight-related condition, and treatment of moderate to severe obstructive sleep apnea in adults with obesity. The Wegovy label covers weight management in adults and patients aged 12 and over, reduction of major adverse cardiovascular events in adults with established cardiovascular disease plus obesity or overweight, and, under accelerated approval, noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. Foundayo is indicated for weight reduction and long-term maintenance.
Those are not marketing lines. They are the reasons an insurer will consider paying and the basis on which a prescriber documents a case. Someone with sleep apnea or established cardiovascular disease is in a different conversation from someone whose only goal is weight, and the brand shelf is where that conversation happens. Ro carries all of the products above, and it discloses that Ozempic is approved for type 2 diabetes and may be prescribed off-label for weight at a provider’s discretion.
A compounded semaglutide or tirzepatide preparation has no indication of its own, because it has no FDA approval and no approved labeling. Mochi says so directly on its catalog page. That does not make the pathway illegitimate, since licensed prescribers and pharmacies work inside a defined legal framework. It does mean a compounded route cannot be chosen on the strength of a labeled indication, because there is none to point at.
Coverage status changes which model is even worth trying
If a plan covers anti-obesity medication, the brand route usually wins on cost. Ro is built for that scenario: a free coverage check, then a concierge that verifies benefits and submits prior authorization paperwork, with one to three weeks quoted for the process and eligibility answered within two days. Covered prescriptions route to a retail pharmacy, cash prescriptions ship to the door.
Mochi runs a lighter version of the same service, asking for insurance details at signup, offering support with prior authorizations and letters of medical necessity, and noting that insurers have 30 days to respond. Its distinct move is a second membership tier priced lower for members with qualifying insurance, which applies to the service fee rather than to the drug.
If a plan excludes the category, both routes collapse to cash and the question becomes which cash structure suits the case. Medicare drug benefits have excluded agents used only for weight reduction, and commercial coverage varies by employer and by the state benchmark plan that defines essential health benefits, so it is worth checking the formulary rather than assuming.
How much clinician contact do you actually want
The two services buy different amounts of human time. Mochi describes scheduled video visits with a board certified physician and with a registered dietitian, a first appointment inside a week of signing up, self-scheduling during onboarding, the ability to switch providers through the portal, and a four-phase structure that sets a health baseline, plans labs or scans, adjusts the plan and rechecks labs before maintenance. Its stated provider bench spans obstetrics and gynecology, bariatric surgery, internal medicine, pediatrics, family medicine, endocrinology and cardiothoracic surgery.
Ro leans asynchronous. The membership includes unlimited provider messaging, regular check-ins, coaching, side effect management, titration support, dose logging and lab testing where necessary, with eligibility determined from an online visit rather than a scheduled call. For someone who wants a fast route to a prescription, that is a feature. For someone who wants a dietitian on video and a named physician to rebook with, it is a gap.
Cost structure follows from that choice, and posted pricing is what lets a reader test it. A provider that names the pathway, the molecule and the monthly figure on one screen can be assessed before intake. One that shows a starting rate and settles the balance afterward cannot. Several smaller cash-pay programs sit in the first group, among them Henry Meds, Eden and the flat-rate service published at formblends.com, and side-by-side pages any of them write about rivals are worth reading for the criteria raised rather than the conclusions reached.
| Reader situation | Which structure fits | What to verify first |
|---|---|---|
| Plan covers anti-obesity medication | Brand-only telehealth with coverage handling | Which products the platform will bill, and the turnaround |
| Sleep apnea, cardiovascular disease or liver disease alongside obesity | Brand product with a matching labeled indication | The indication text on the current label, not a marketing summary |
| No coverage, budget is the binding constraint | Flat-rate compounded membership | That the price holds at the top of the dose range, and who dispenses |
| Wants video visits and dietitian input | Membership built around appointments | Visit frequency, who attends, whether visits cost extra |
| Wants the fastest route to a first dose | Asynchronous intake with cash-pay shipping | Stated eligibility and shipping timelines, in writing |
| Patient is under 18 | A program stating a pediatric pathway | Whether the prescriber is credentialed for that age group |
Medical history that narrows the field before price does
Some history rules out the whole drug class regardless of vendor. The approved labels for these products contraindicate use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, a warning Ro reproduces on its weight loss pages. Pancreatitis history, gallbladder disease, diabetic retinopathy and concurrent insulin or sulfonylurea use all belong in the intake, whichever company receives it.
Age matters too. Mochi states that it runs a program for patients under 18, and the Wegovy label extends to patients aged 12 and older, so an adolescent case has a documented route on the brand side. Prediabetes, type 2 diabetes or hypertension exclude nobody from either service, but they change which molecule a prescriber reaches for and whether a diabetes indication opens a coverage path a weight indication does not.
Goals often extend past weight, and several of these companies run more than one category, which is worth naming before signing up. Ro and Hims and Hers both operate men’s health lines beside their GLP-1 programs, and a provider such as HealthRX, which publishes its own ED treatment options, sits in that multi-category group alongside single-purpose weight services. Someone whose list of reasons for the visit runs wider than the scale may find that matching the provider to every goal, rather than to one drug, avoids enrolling twice.
Frequently asked questions
Does a broader medication list make one provider better?
Not on its own. Mochi lists older oral agents such as topiramate, bupropion, naltrexone and orlistat alongside the GLP-1 drugs, which suits people who cannot tolerate or afford injectables. Ro concentrates on approved GLP-1 products. Breadth helps only if the extra options match the case in front of the prescriber.
How much does state of residence affect the choice?
More than most buyers expect. Mochi states that its promotional first-month rate is not available in all states and that terms vary by state. Telehealth prescribing rules, pharmacy licensure and refund requirements are all state-level, so the offer seen at checkout may differ from the one advertised nationally.
Is a named dispensing pharmacy something to insist on?
It is a reasonable thing to ask. Insured fills through Ro go to a pharmacy the patient already uses, which is transparent by design. For compounded products the dispensing facility is the entity responsible for the preparation, and knowing which one it is makes any later question about a specific batch answerable.
Do the published average results help with the choice?
Only a little. Both companies publish average outcome figures drawn from their own members, and Ro discloses that its featured testimonials were paid. Company-reported averages are not trial results and are not comparable across platforms, so they belong well below labeling and coverage in any decision.
